The inspection took place between June 22 and June 30, 2026. At its conclusion, the company received a Form 483 detailing six observations.
Glenmark confirmed that none of the observations pertained to data integrity and that there were no repeat issues. The company categorized the observations as procedural. They added that they do not foresee any effect on the supply of their commercial products.
ALSO READ | Glenmark Pharma Q4 net profit soars to ₹301 crore; endorses 250% dividend
Glenmark further stated that it will collaborate closely with the US FDA to address the observations and will submit its response to the regulator within the designated timeframe.
What is a Form 483
A Form 483 is a compilation of observations made during the inspection, issued by the USFDA inspectors after the inspection concludes. These observations are communicated and explained to the supplier during the closing conference. However, a Form 483 does not constitute a conclusive FDA judgment regarding the facility’s GMP compliance.
After the issuance of Form 483, the company is allotted 15 days to respond to the USFDA, outlining the steps it will take to rectify the observations identified by the USFDA.
ALSO READ | Glenmark’s US division settles generic drug pricing dispute for $29.6 million
This month, Glenmark Pharmaceuticals announced a projected FY27 revenue of ₹17,000-18,000 crore, with EBITDA margins anticipated to stay within the 21-22% range.
Anurag Mantri, Executive Director & Global Chief Financial Officer, emphasized ongoing momentum in India, growth in the US respiratory and injectable markets, and new product introductions across Europe and emerging markets as pivotal factors for future progress.
Mantri also outlined Glenmark’s long-term goal of transforming into a global innovation-driven pharmaceutical firm. Currently, branded products account for about 60% of revenue, and the company aims for a 70% share by 2030 through a blend of in-licensed therapies, specialty products, and global brand expansion.
ALSO READ | Glenmark Pharma Q3: Profit and revenue rise over 15% as India and North America drive growth
Shares of Glenmark Pharmaceuticals Ltd closed at ₹2,204.90, falling by ₹18.70, or 0.86%, on the BSE.
